D2B enables the discovery of potent S. aureus TrmD inhibitors

In a great collaboration with the Ziebuhr Lab and the Wolf Lab, we have developed a Direct-to-Biology (D2B) pipeline for the discovery of potent S. aureus TrmD inhibitors.
Check out the recent publication in Journal of Medicinal Chemistry: Nanoscale Direct-to-Biology Optimization and Structural Insights into Selective S. aureus TrmD Inhibitors